Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 2/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13575129 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL16104620 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL9496434 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL9159602 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL30515121 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL9495170 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL15070694 | 0.87 | CASR (0.47) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL10411750 | 0.86 | SLC6A1 (0.39) | KIF11KCNH2CASRSLC6A1SLC6A11 | |
| SCHEMBL13160566 | 0.85 | KIF11 (0.52) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL10412255 | 0.85 | CASR (0.46) | KIF11KCNH2CASRSLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| EP-1538154-A1 | Quencher composition comprising anthraquinone moieties | Exiqon A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| EP-0898596-B1 | SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD | AMERSHAM PHARM BIOTECH UK LTD (GB) | 2001-08-29 | — | — | EP | disclosed |
| US-6140494-A | INCREASED WATER SOLUBILITY, INCREASED PHOTOSTABILITY, BRIGHTNESS AND THE POTENTIAL REDUCTION OF INTERACTIONS WITH SURROUNDINGS | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 2000-10-31 | — | — | US | disclosed |
| EP-0898596-A1 | SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD | Amersham Pharmacia Biotech UK Limited (GB) | 1999-03-03 | — | — | EP | disclosed |
| WO-1997040104-A1 | SQUARATE DYES AND THEIR USE IN FLUORESCENT SEQUENCING METHOD | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | KIF11 4653/4885KCNH2 2949/4885CASR 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.